Regeneron Reports Positive Phase 3 Data for EYLEAA Injection in Macular Edema Following Branch Retinal Vein Occlusion TARRYTOWN, N.Y., /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEAA Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion .
http://www.biospace.com/news_story.aspx?StoryID=312311&full=1
http://www.biospace.com/news_story.aspx?StoryID=312311&full=1
No comments:
Post a Comment